Management of Locally Advanced Esophageal Cancer

Nicolas Zhou; Ravi Rajaram; Wayne L. Hofstetter

doi:10.1016/j.soc.2020.06.003

Management of Locally Advanced Esophageal Cancer

Nicolas Zhou, Ravi Rajaram, Wayne L. Hofstetter

Thoracic & Cardiovascular Surgery

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Management of locally advanced esophageal cancer is evolving. Trimodality therapy with chemoradiation followed by surgical resection has become the standard of care. However, the value of planned surgery after response to therapy is in question. In this article, we discuss the current practice principles and evidence for the treatment of locally advanced esophageal cancer. Topics will include various neoadjuvant therapies, trimodality versus bimodality therapy, and outcomes for salvage esophagectomies. In addition, emerging novel therapies, such as HER2 inhibitors and immunotherapy, are available for unresectable or metastatic disease, enabling a greater armamentarium of tumor biology-specific treatments.

Original language	English (US)
Pages (from-to)	631-646
Number of pages	16
Journal	Surgical oncology clinics of North America
Volume	29
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2020.06.003
State	Published - Oct 2020

Keywords

Adenocarcinoma
Chemoradiation
Esophageal cancer
HER2
MSI
PD-L1
Salvage
Squamous cell carcinoma

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2020.06.003

Cite this

@article{5b693aa3e78546889e781a0b3b8a8b58,

title = "Management of Locally Advanced Esophageal Cancer",

abstract = "Management of locally advanced esophageal cancer is evolving. Trimodality therapy with chemoradiation followed by surgical resection has become the standard of care. However, the value of planned surgery after response to therapy is in question. In this article, we discuss the current practice principles and evidence for the treatment of locally advanced esophageal cancer. Topics will include various neoadjuvant therapies, trimodality versus bimodality therapy, and outcomes for salvage esophagectomies. In addition, emerging novel therapies, such as HER2 inhibitors and immunotherapy, are available for unresectable or metastatic disease, enabling a greater armamentarium of tumor biology-specific treatments.",

keywords = "Adenocarcinoma, Chemoradiation, Esophageal cancer, HER2, MSI, PD-L1, Salvage, Squamous cell carcinoma",

author = "Nicolas Zhou and Ravi Rajaram and Hofstetter, {Wayne L.}",

year = "2020",

month = oct,

doi = "10.1016/j.soc.2020.06.003",

language = "English (US)",

volume = "29",

pages = "631--646",

journal = "Surgical oncology clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Management of Locally Advanced Esophageal Cancer

AU - Zhou, Nicolas

AU - Rajaram, Ravi

AU - Hofstetter, Wayne L.

PY - 2020/10

Y1 - 2020/10

N2 - Management of locally advanced esophageal cancer is evolving. Trimodality therapy with chemoradiation followed by surgical resection has become the standard of care. However, the value of planned surgery after response to therapy is in question. In this article, we discuss the current practice principles and evidence for the treatment of locally advanced esophageal cancer. Topics will include various neoadjuvant therapies, trimodality versus bimodality therapy, and outcomes for salvage esophagectomies. In addition, emerging novel therapies, such as HER2 inhibitors and immunotherapy, are available for unresectable or metastatic disease, enabling a greater armamentarium of tumor biology-specific treatments.

AB - Management of locally advanced esophageal cancer is evolving. Trimodality therapy with chemoradiation followed by surgical resection has become the standard of care. However, the value of planned surgery after response to therapy is in question. In this article, we discuss the current practice principles and evidence for the treatment of locally advanced esophageal cancer. Topics will include various neoadjuvant therapies, trimodality versus bimodality therapy, and outcomes for salvage esophagectomies. In addition, emerging novel therapies, such as HER2 inhibitors and immunotherapy, are available for unresectable or metastatic disease, enabling a greater armamentarium of tumor biology-specific treatments.

KW - Adenocarcinoma

KW - Chemoradiation

KW - Esophageal cancer

KW - HER2

KW - MSI

KW - PD-L1

KW - Salvage

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85088221114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088221114&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2020.06.003

DO - 10.1016/j.soc.2020.06.003

M3 - Review article

C2 - 32883463

AN - SCOPUS:85088221114

SN - 1055-3207

VL - 29

SP - 631

EP - 646

JO - Surgical oncology clinics of North America

JF - Surgical oncology clinics of North America

IS - 4

ER -

Management of Locally Advanced Esophageal Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this